{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:25:40Z","timestamp":1793175940403,"version":"4.5.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41574-020-0382-4","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T13:50:10Z","timestamp":1595944210000},"page":"578-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Pathogenesis and treatment of primary aldosteronism"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-9191","authenticated-orcid":false,"given":"Maria-Christina","family":"Zennaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheerazed","family":"Boulkroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-0792","authenticated-orcid":false,"given":"Fabio L.","family":"Fernandes-Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"382_CR1","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone, S. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69, 1811\u20131820 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"382_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0031-1295438","volume":"44","author":"A Hannemann","year":"2012","unstructured":"Hannemann, A. & Wallaschofski, H. Prevalence of primary aldosteronism in patient\u2019s cohorts and in population-based studies \u2014 a review of the current literature. Horm. Metab. Res. 44, 157\u2013162 (2012).","journal-title":"Horm. Metab. Res."},{"key":"382_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"Brown, J. M. et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann. Intern. Med. 173, 10\u201320 (2020).","journal-title":"Ann. Intern. Med."},{"key":"382_CR4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder, J. W. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889\u20131916 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.111.175083","volume":"58","author":"P Mulatero","year":"2011","unstructured":"Mulatero, P. et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 58, 797\u2013803 (2011).","journal-title":"Hypertension"},{"key":"382_CR6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"Lifton, R. P. et al. A chimaeric 11beta-hydroxylase aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355, 262\u2013265 (1992).","journal-title":"Nature"},{"key":"382_CR7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","volume":"331","author":"M Choi","year":"2011","unstructured":"Choi, M. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768\u2013772 (2011).","journal-title":"Science"},{"key":"382_CR8","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06315","volume":"4","author":"UI Scholl","year":"2015","unstructured":"Scholl, U. I. et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. eLife 4, e06315 (2015).","journal-title":"eLife"},{"key":"382_CR9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","volume":"50","author":"UI Scholl","year":"2018","unstructured":"Scholl, U. I. et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat. Genet. 50, 349\u2013354 (2018).","journal-title":"Nat. Genet."},{"key":"382_CR10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","volume":"50","author":"FL Fernandes-Rosa","year":"2018","unstructured":"Fernandes-Rosa, F. L. et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat. Genet. 50, 355\u2013361 (2018).","journal-title":"Nat. Genet."},{"key":"382_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1152\/physrev.00011.2014","volume":"95","author":"BC Rossier","year":"2015","unstructured":"Rossier, B. C., Baker, M. E. & Studer, R. A. Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol. Rev. 95, 297\u2013340 (2015).","journal-title":"Physiol. Rev."},{"key":"382_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","volume":"62","author":"S Savard","year":"2013","unstructured":"Savard, S., Amar, L., Plouin, P. F. & Steichen, O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 62, 331\u2013336 (2013).","journal-title":"Hypertension"},{"key":"382_CR13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone, S. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41\u201350 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"382_CR14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243\u20131248 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"382_CR15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","volume":"19","author":"GP Rossi","year":"2008","unstructured":"Rossi, G. P. et al. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol. Metab. 19, 88\u201390 (2008).","journal-title":"Trends Endocrinol. Metab."},{"key":"382_CR16","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi, G. P. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293\u20132300 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"382_CR17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jc.2008-2116","volume":"94","author":"E Born-Frontsberg","year":"2009","unstructured":"Born-Frontsberg, E. et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn\u2019s Registry. J. Clin. Endocrinol. Metab. 94, 1125\u20131130 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR18","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","volume":"95","author":"GP Rossi","year":"1997","unstructured":"Rossi, G. P. et al. Remodeling of the left ventricle in primary aldosteronism due to Conn\u2019s adenoma. Circulation 95, 1471\u20131478 (1997).","journal-title":"Circulation"},{"key":"382_CR19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCIMAGING.112.974576","volume":"5","author":"EM Freel","year":"2012","unstructured":"Freel, E. M. et al. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circ. Cardiovasc. Imaging 5, 740\u2013747 (2012).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"382_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","volume":"13","author":"JA Leopold","year":"2007","unstructured":"Leopold, J. A. et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13, 189\u2013197 (2007).","journal-title":"Nat. Med."},{"key":"382_CR21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","volume":"14","author":"NJ Brown","year":"2005","unstructured":"Brown, N. J. Aldosterone and end-organ damage. Curr. Opin. Nephrol. Hypertens. 14, 235\u2013241 (2005).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"382_CR22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","volume":"64","author":"DA Calhoun","year":"2013","unstructured":"Calhoun, D. A. Hyperaldosteronism as a common cause of resistant hypertension. Annu. Rev. Med. 64, 233\u2013247 (2013).","journal-title":"Annu. Rev. Med."},{"key":"382_CR23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","volume":"285","author":"WF Young Jr.","year":"2019","unstructured":"Young, W. F. Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J. Intern. Med. 285, 126\u2013148 (2019).","journal-title":"J. Intern. Med."},{"key":"382_CR24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","volume":"58","author":"T Nishikawa","year":"2011","unstructured":"Nishikawa, T. et al. Guidelines for the diagnosis and treatment of primary aldosteronism \u2014 the Japan Endocrine Society 2009. Endocr. J. 58, 711\u2013721 (2011).","journal-title":"Endocr. J."},{"key":"382_CR25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1373\/clinchem.2015.251199","volume":"62","author":"G Eisenhofer","year":"2016","unstructured":"Eisenhofer, G. et al. Mass spectrometry-based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism. Clin. Chem. 62, 514\u2013524 (2016).","journal-title":"Clin. Chem."},{"key":"382_CR26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/HYPERTENSIONAHA.119.13866","volume":"75","author":"AF Turcu","year":"2020","unstructured":"Turcu, A. F. et al. Comprehensive analysis of steroid biomarkers for guiding primary aldosteronism subtyping. Hypertension 75, 183\u2013192 (2020).","journal-title":"Hypertension"},{"key":"382_CR27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","volume":"4","author":"T Dekkers","year":"2016","unstructured":"Dekkers, T. et al. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 4, 739\u2013746 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"382_CR28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/HYPERTENSIONAHA.116.08820","volume":"69","author":"GP Rossi","year":"2017","unstructured":"Rossi, G. P. & Funder, J. W. Adrenal venous sampling versus computed tomographic scan to determine treatment in primary aldosteronism (the SPARTACUS trial): a critique. Hypertension 69, 396\u2013397 (2017).","journal-title":"Hypertension"},{"key":"382_CR29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/HYPERTENSIONAHA.118.11382","volume":"72","author":"TA Williams","year":"2018","unstructured":"Williams, T. A. et al. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension 72, 641\u2013649 (2018).","journal-title":"Hypertension"},{"key":"382_CR30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/HYPERTENSIONAHA.119.13463","volume":"74","author":"GP Rossi","year":"2019","unstructured":"Rossi, G. P. et al. Clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling. Hypertension 74, 800\u2013808 (2019).","journal-title":"Hypertension"},{"key":"382_CR31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1440-1681.1992.tb00462.x","volume":"19","author":"M Stowasser","year":"1992","unstructured":"Stowasser, M. et al. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin. Exp. Pharmacol. Physiol. 19, 319\u2013322 (1992).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"382_CR32","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","volume":"93","author":"DS Geller","year":"2008","unstructured":"Geller, D. S. et al. A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab. 93, 3117\u20133123 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR33","first-page":"1109","volume":"95","author":"DJ Sutherland","year":"1966","unstructured":"Sutherland, D. J., Ruse, J. L. & Laidlaw, J. C. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can. Med. Assoc. J. 95, 1109\u20131119 (1966).","journal-title":"Can. Med. Assoc. J."},{"key":"382_CR34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ecl.2011.01.012","volume":"40","author":"F Halperin","year":"2011","unstructured":"Halperin, F. & Dluhy, R. G. Glucocorticoid-remediable aldosteronism. Endocrinol. Metab. Clin. North Am. 40, 333\u2013341 (2011).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"382_CR35","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1073\/pnas.89.17.8327","volume":"89","author":"L Pascoe","year":"1992","unstructured":"Pascoe, L. et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc. Natl Acad. Sci. USA 89, 8327\u20138331 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"382_CR36","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1172\/JCI118279","volume":"96","author":"L Pascoe","year":"1995","unstructured":"Pascoe, L. et al. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J. Clin. Invest. 96, 2236\u20132246 (1995).","journal-title":"J. Clin. Invest."},{"key":"382_CR37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00004872-200018090-00002","volume":"18","author":"M Stowasser","year":"2000","unstructured":"Stowasser, M. & Gordon, R. D. Primary aldosteronism: learning from the study of familial varieties. J. Hypertens. 18, 1165\u20131176 (2000).","journal-title":"J. Hypertens."},{"key":"382_CR38","first-page":"3996","volume":"83","author":"P Mulatero","year":"1998","unstructured":"Mulatero, P. et al. Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. J. Clin. Endocrinol. Metab. 83, 3996\u20134001 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR39","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1210\/jcem.83.7.4946","volume":"83","author":"P Mulatero","year":"1998","unstructured":"Mulatero, P. et al. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J. Clin. Endocrinol. Metab. 83, 2573\u20132575 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0960-0760(01)00097-8","volume":"78","author":"M Stowasser","year":"2001","unstructured":"Stowasser, M. & Gordon, R. D. Familial hyperaldosteronism. J. Steroid Biochem. Mol. Biol. 78, 215\u2013229 (2001).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"382_CR41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0003-4266(05)81756-1","volume":"66","author":"V Medeau","year":"2005","unstructured":"Medeau, V. et al. Familial aspect of primary hyperaldosteronism: analysis of families compatible with primary hyperaldosteronism type 2. Ann. Endocrinol. 66, 240\u2013246 (2005).","journal-title":"Ann. Endocrinol."},{"key":"382_CR42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0031-1299730","volume":"44","author":"A Pallauf","year":"2012","unstructured":"Pallauf, A. et al. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. Horm. Metab. Res. 44, 215\u2013220 (2012).","journal-title":"Horm. Metab. Res."},{"key":"382_CR43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/HYPERTENSIONAHA.111.183996","volume":"59","author":"P Mulatero","year":"2012","unstructured":"Mulatero, P. et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 59, 235\u2013240 (2012).","journal-title":"Hypertension"},{"key":"382_CR44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2016.10.002","volume":"13","author":"G Daniil","year":"2016","unstructured":"Daniil, G. et al. CACNA1H mutations are associated with different forms of primary aldosteronism. EBioMedicine 13, 225\u2013236 (2016).","journal-title":"EBioMedicine"},{"key":"382_CR45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/a-0713-0629","volume":"127","author":"LG Perez-Rivas","year":"2019","unstructured":"Perez-Rivas, L. G., Williams, T. A. & Reincke, M. Inherited forms of primary hyperaldosteronism: new genes, new phenotypes and proposition of a new classification. Exp. Clin. Endocrinol. Diabetes 127, 93\u201399 (2019).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"382_CR46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrendo.2012.230","volume":"9","author":"P Mulatero","year":"2013","unstructured":"Mulatero, P., Monticone, S., Rainey, W. E., Veglio, F. & Williams, T. A. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat. Rev. Endocrinol. 9, 104\u2013112 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"382_CR47","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1073\/pnas.1121407109","volume":"109","author":"UI Scholl","year":"2012","unstructured":"Scholl, U. I. et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc. Natl Acad. Sci. USA 109, 2533\u20132538 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"382_CR48","doi-asserted-by":"crossref","first-page":"E1861","DOI":"10.1210\/jc.2013-2428","volume":"98","author":"S Monticone","year":"2013","unstructured":"Monticone, S. et al. A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J. Clin. Endocrinol. Metab. 98, E1861\u2013E1865 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000358197","volume":"82","author":"M Adachi","year":"2014","unstructured":"Adachi, M. et al. Discordant genotype\u2013phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature. Horm. Res. Paediatr. 82, 138\u2013142 (2014).","journal-title":"Horm. Res. Paediatr."},{"key":"382_CR50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mce.2016.10.025","volume":"439","author":"CE Gomez-Sanchez","year":"2017","unstructured":"Gomez-Sanchez, C. E. et al. Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3. Mol. Cell Endocrinol. 439, 74\u201380 (2017).","journal-title":"Mol. Cell Endocrinol."},{"key":"382_CR51","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1210\/jc.2016-1504","volume":"101","author":"A Tong","year":"2016","unstructured":"Tong, A. et al. A novel phenotype of familial hyperaldosteronism type III: concurrence of aldosteronism and Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 101, 4290\u20134297 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR52","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","volume":"45","author":"UI Scholl","year":"2013","unstructured":"Scholl, U. I. et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat. Genet. 45, 1050\u20131054 (2013).","journal-title":"Nat. Genet."},{"key":"382_CR53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.17116\/jnevro201811812149","volume":"118","author":"NA Semenova","year":"2018","unstructured":"Semenova, N. A., Ryzhkova, O. R., Strokova, T. V. & Taran, N. N. The third case report a patient with primary aldosteronism, seizures, and neurologic abnormalities (PASNA) syndrome de novo variant mutations in the CACNA1D gene [Russian]. Zh Nevrol. Psikhiatr Im. S S Korsakova 118, 49\u201352 (2018).","journal-title":"Zh Nevrol. Psikhiatr Im. S S Korsakova"},{"key":"382_CR54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19336950.2020.1761171","volume":"14","author":"MC De Mingo Alemany","year":"2020","unstructured":"De Mingo Alemany, M. C., Mifsud Grau, L., Moreno Macian, F., Ferrer Lorente, B. & Leon Carinena, S. A de novo CACNA1D missense mutation in a patient with congenital hyperinsulinism, primary hyperaldosteronism and hypotonia. Channels 14, 175\u2013180 (2020).","journal-title":"Channels"},{"key":"382_CR55","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/pedi.12512","volume":"18","author":"SE Flanagan","year":"2017","unstructured":"Flanagan, S. E. et al. A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia. Pediatr. Diabetes 18, 320\u2013323 (2017).","journal-title":"Pediatr. Diabetes"},{"key":"382_CR56","doi-asserted-by":"crossref","first-page":"E1341","DOI":"10.1210\/jc.2013-4255","volume":"99","author":"T Dekkers","year":"2014","unstructured":"Dekkers, T. et al. Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit? J. Clin. Endocrinol. Metab. 99, E1341\u2013E1351 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR57","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/meta.2002.30498","volume":"51","author":"M Omura","year":"2002","unstructured":"Omura, M., Sasano, H., Fujiwara, T., Yamaguchi, K. & Nishikawa, T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 51, 350\u2013355 (2002).","journal-title":"Metabolism"},{"key":"382_CR58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.mce.2015.04.022","volume":"411","author":"S Monticone","year":"2015","unstructured":"Monticone, S. et al. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol. Cell Endocrinol. 411, 146\u2013154 (2015).","journal-title":"Mol. Cell Endocrinol."},{"key":"382_CR59","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/HYPERTENSIONAHA.115.05993","volume":"66","author":"FL Fernandes-Rosa","year":"2015","unstructured":"Fernandes-Rosa, F. L. et al. Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma. Hypertension 66, 1014\u20131022 (2015).","journal-title":"Hypertension"},{"key":"382_CR60","first-page":"1182","volume":"102","author":"Y Yamazaki","year":"2017","unstructured":"Yamazaki, Y. et al. Histopathological classification of cross-sectional image-negative hyperaldosteronism. J. Clin. Endocrinol. Metab. 102, 1182\u20131192 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR61","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.2716","volume":"45","author":"EA Azizan","year":"2013","unstructured":"Azizan, E. A. et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat. Genet. 45, 1055\u20131060 (2013).","journal-title":"Nat. Genet."},{"key":"382_CR62","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng.2550","volume":"45","author":"F Beuschlein","year":"2013","unstructured":"Beuschlein, F. et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat. Genet. 45, 440\u2013444 (2013).","journal-title":"Nat. Genet."},{"key":"382_CR63","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","volume":"64","author":"FL Fernandes-Rosa","year":"2014","unstructured":"Fernandes-Rosa, F. L. et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 64, 354\u2013361 (2014).","journal-title":"Hypertension"},{"key":"382_CR64","doi-asserted-by":"crossref","first-page":"E1089","DOI":"10.1210\/jc.2015-2149","volume":"100","author":"L Lenzini","year":"2015","unstructured":"Lenzini, L. et al. A meta-analysis of somatic KCNJ5 K+ channel mutations in 1636 patients with an aldosterone-producing adenoma. J. Clin. Endocrinol. Metab. 100, E1089\u2013E1095 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR65","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1210\/er.2017-00189","volume":"38","author":"MC Zennaro","year":"2017","unstructured":"Zennaro, M. C., Boulkroun, S. & Fernandes-Rosa, F. Genetic causes of functional adrenocortical adenomas. Endocr. Rev. 38, 516\u2013537 (2017).","journal-title":"Endocr. Rev."},{"key":"382_CR66","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/cen.12873","volume":"83","author":"UI Scholl","year":"2015","unstructured":"Scholl, U. I. et al. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin. Endocrinol. 83, 779\u2013789 (2015).","journal-title":"Clin. Endocrinol."},{"key":"382_CR67","doi-asserted-by":"crossref","DOI":"10.1038\/srep19546","volume":"6","author":"T Akerstrom","year":"2016","unstructured":"Akerstrom, T. et al. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci. Rep. 6, 19546 (2016).","journal-title":"Sci. Rep."},{"key":"382_CR68","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1504869","volume":"373","author":"AE Teo","year":"2015","unstructured":"Teo, A. E. et al. Pregnancy, primary aldosteronism, and adrenal CTNNB1 mutations. N. Engl. J. Med. 373, 1429\u20131436 (2015).","journal-title":"N. Engl. J. Med."},{"key":"382_CR69","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2016-1700","volume":"101","author":"Y Rhayem","year":"2016","unstructured":"Rhayem, Y. et al. PRKACA somatic mutations are rare findings in aldosterone-producing adenomas. J. Clin. Endocrinol. Metab. 101, 3010\u20133017 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR70","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2265.2007.03033.x","volume":"68","author":"M Tadjine","year":"2008","unstructured":"Tadjine, M., Lampron, A., Ouadi, L. & Bourdeau, I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin. Endocrinol. 68, 264\u2013270 (2008).","journal-title":"Clin. Endocrinol."},{"key":"382_CR71","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","volume":"65","author":"F Tissier","year":"2005","unstructured":"Tissier, F. et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65, 7622\u20137627 (2005).","journal-title":"Cancer Res."},{"key":"382_CR72","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1310359","volume":"370","author":"F Beuschlein","year":"2014","unstructured":"Beuschlein, F. et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing\u2019s syndrome. N. Engl. J. Med. 370, 1019\u20131028 (2014).","journal-title":"N. Engl. J. Med."},{"key":"382_CR73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1126\/science.1249480","volume":"344","author":"Y Cao","year":"2014","unstructured":"Cao, Y. et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing\u2019s syndrome. Science 344, 913\u2013917 (2014).","journal-title":"Science"},{"key":"382_CR74","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1126\/science.1252328","volume":"344","author":"Y Sato","year":"2014","unstructured":"Sato, Y. et al. Recurrent somatic mutations underlie corticotropin-independent Cushing\u2019s syndrome. Science 344, 917\u2013920 (2014).","journal-title":"Science"},{"key":"382_CR75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2956","volume":"46","author":"G Goh","year":"2014","unstructured":"Goh, G. et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat. Genet. 46, 613\u2013617 (2014).","journal-title":"Nat. Genet."},{"key":"382_CR76","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2018-01004","volume":"103","author":"K Nanba","year":"2018","unstructured":"Nanba, K. et al. Targeted molecular characterization of aldosterone-producing adenomas in white Americans. J. Clin. Endocrinol. Metab. 103, 3869\u20133876 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR77","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","volume":"73","author":"K Nanba","year":"2019","unstructured":"Nanba, K. et al. Genetic characteristics of aldosterone-producing adenomas in blacks. Hypertension 73, 885\u2013892 (2019).","journal-title":"Hypertension"},{"key":"382_CR78","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.119.14177","volume":"75","author":"K De Sousa","year":"2020","unstructured":"De Sousa, K. et al. Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma. Hypertension 75, 1034\u20131044 (2020).","journal-title":"Hypertension"},{"key":"382_CR79","doi-asserted-by":"crossref","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","volume":"112","author":"K Nishimoto","year":"2015","unstructured":"Nishimoto, K. et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc. Natl Acad. Sci. USA 112, E4591\u2013E4599 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"382_CR80","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","volume":"72","author":"K Omata","year":"2018","unstructured":"Omata, K. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 72, 874\u2013880 (2018).","journal-title":"Hypertension"},{"key":"382_CR81","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1152\/physrev.00030.2003","volume":"84","author":"A Spat","year":"2004","unstructured":"Spat, A. & Hunyady, L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol. Rev. 84, 489\u2013539 (2004).","journal-title":"Physiol. Rev."},{"key":"382_CR82","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1210\/en.2012-1241","volume":"153","author":"K Oki","year":"2012","unstructured":"Oki, K., Plonczynski, M. W., Lam, M. L., Gomez-Sanchez, E. P. & Gomez-Sanchez, C. E. The potassium channel, Kir3.4, participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line. Endocrinology 153, 4328\u20134335 (2012).","journal-title":"Endocrinology"},{"key":"382_CR83","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/HJH.0b013e328356139f","volume":"30","author":"M Murthy","year":"2012","unstructured":"Murthy, M., Azizan, E. A., Brown, M. J. & O\u2019Shaughnessy, K. M. Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma. J. Hypertens. 30, 1827\u20131833 (2012).","journal-title":"J. Hypertens."},{"key":"382_CR84","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1210\/jc.2014-3009","volume":"100","author":"CJ Cheng","year":"2015","unstructured":"Cheng, C. J. et al. Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane abundance. J. Clin. Endocrinol. Metab. 100, E155\u2013E163 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR85","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/HYPERTENSIONAHA.119.13476","volume":"74","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Primary aldosteronism: KCNJ5 mutations and adrenocortical cell growth. Hypertension 74, 809\u2013816 (2019).","journal-title":"Hypertension"},{"key":"382_CR86","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1152\/physrev.00047.2017","volume":"98","author":"TJ Jentsch","year":"2018","unstructured":"Jentsch, T. J. & Pusch, M. CLC chloride channels and transporters: structure, function, physiology, and disease. Physiol. Rev. 98, 1493\u20131590 (2018).","journal-title":"Physiol. Rev."},{"key":"382_CR87","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/360759a0","volume":"360","author":"S Grunder","year":"1992","unstructured":"Grunder, S., Thiemann, A., Pusch, M. & Jentsch, T. J. Regions involved in the opening of CIC-2 chloride channel by voltage and cell volume. Nature 360, 759\u2013762 (1992).","journal-title":"Nature"},{"key":"382_CR88","doi-asserted-by":"crossref","first-page":"K37","DOI":"10.1530\/EJE-19-0377","volume":"181","author":"RK Dutta","year":"2019","unstructured":"Dutta, R. K. et al. A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma. Eur. J. Endocrinol. 181, K37\u2013K41 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"382_CR89","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12113-9","volume":"10","author":"C Goppner","year":"2019","unstructured":"Goppner, C. et al. Pathogenesis of hypertension in a mouse model for human CLCN2 related hyperaldosteronism. Nat. Commun. 10, 4678 (2019).","journal-title":"Nat. Commun."},{"key":"382_CR90","volume":"10","author":"J Schewe","year":"2019","unstructured":"Schewe, J. et al. Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation. Nat. Commun. 10, 5155 (2019).","journal-title":"Nat. Commun."},{"key":"382_CR91","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1210\/en.2015-1466","volume":"156","author":"J Stindl","year":"2015","unstructured":"Stindl, J. et al. Pathogenesis of adrenal aldosterone-producing adenomas carrying mutations of the Na+\/K+-ATPase. Endocrinology 156, 4582\u20134591 (2015).","journal-title":"Endocrinology"},{"key":"382_CR92","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev.biochem.71.102201.141218","volume":"71","author":"JH Kaplan","year":"2002","unstructured":"Kaplan, J. H. Biochemistry of Na,K-ATPase. Annu. Rev. Biochem. 71, 511\u2013535 (2002).","journal-title":"Annu. Rev. Biochem."},{"key":"382_CR93","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/HYPERTENSIONAHA.113.01733","volume":"63","author":"TA Williams","year":"2014","unstructured":"Williams, T. A. et al. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension 63, 188\u2013195 (2014).","journal-title":"Hypertension"},{"key":"382_CR94","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/HYPERTENSIONAHA.114.03346","volume":"65","author":"FF Zheng","year":"2015","unstructured":"Zheng, F. F. et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension 65, 622\u2013628 (2015).","journal-title":"Hypertension"},{"key":"382_CR95","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1530\/ERC-15-0321","volume":"22","author":"T Akerstrom","year":"2015","unstructured":"Akerstrom, T. et al. Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas. Endocr. Relat. Cancer 22, 735\u2013744 (2015).","journal-title":"Endocr. Relat. Cancer"},{"key":"382_CR96","doi-asserted-by":"crossref","first-page":"23854","DOI":"10.1074\/jbc.M702259200","volume":"282","author":"AP Einholm","year":"2007","unstructured":"Einholm, A. P., Andersen, J. P. & Vilsen, B. Importance of Leu99 in transmembrane segment M1 of the Na+, K+-ATPase in the binding and occlusion of K+. J. Biol. Chem. 282, 23854\u201323866 (2007).","journal-title":"J. Biol. Chem."},{"key":"382_CR97","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1530\/ERC-13-0466","volume":"21","author":"RK Dutta","year":"2014","unstructured":"Dutta, R. K. et al. Complementary somatic mutations of KCNJ5, ATP1A1, and ATP2B3 in sporadic aldosterone producing adrenal adenomas. Endocr. Relat. Cancer 21, L1\u2013L4 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"382_CR98","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1210\/en.2015-2029","volume":"157","author":"P Tauber","year":"2016","unstructured":"Tauber, P. et al. Cellular pathophysiology of an adrenal adenoma-associated mutant of the plasma membrane Ca2+-ATPase ATP2B3. Endocrinology 157, 2489\u20132499 (2016).","journal-title":"Endocrinology"},{"key":"382_CR99","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1210\/jc.2015-3285","volume":"101","author":"K Nishimoto","year":"2016","unstructured":"Nishimoto, K. et al. Case report: nodule development from subcapsular aldosterone-producing cell clusters causes hyperaldosteronism. J. Clin. Endocrinol. Metab. 101, 6\u20139 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR100","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1210\/jc.2009-2010","volume":"95","author":"K Nishimoto","year":"2010","unstructured":"Nishimoto, K. et al. Adrenocortical zonation in humans under normal and pathological conditions. J. Clin. Endocrinol. Metab. 95, 2296\u20132305 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR101","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.110.158543","volume":"56","author":"S Boulkroun","year":"2010","unstructured":"Boulkroun, S. et al. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 56, 885\u2013892 (2010).","journal-title":"Hypertension"},{"key":"382_CR102","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.mce.2016.10.014","volume":"441","author":"K Nishimoto","year":"2017","unstructured":"Nishimoto, K. et al. Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism. Mol. Cell Endocrinol. 441, 124\u2013133 (2017).","journal-title":"Mol. Cell Endocrinol."},{"key":"382_CR103","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/HYPERTENSIONAHA.119.14041","volume":"75","author":"N Sun","year":"2020","unstructured":"Sun, N. et al. Mass spectrometry imaging establishes 2 distinct metabolic phenotypes of aldosterone-producing cell clusters in primary aldosteronism. Hypertension 75, 634\u2013644 (2020).","journal-title":"Hypertension"},{"key":"382_CR104","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/en.2011-1205","volume":"152","author":"S Boulkroun","year":"2011","unstructured":"Boulkroun, S. et al. Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem\/progenitor cell markers. Endocrinology 152, 4753\u20134763 (2011).","journal-title":"Endocrinology"},{"key":"382_CR105","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/hmg\/ddt484","volume":"23","author":"A Berthon","year":"2014","unstructured":"Berthon, A. et al. WNT\/beta-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum. Mol. Genet. 23, 889\u2013905 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"382_CR106","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/eje.0.1510073","volume":"151","author":"U Enberg","year":"2004","unstructured":"Enberg, U. et al. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur. J. Endocrinol. 151, 73\u201385 (2004).","journal-title":"Eur. J. Endocrinol."},{"key":"382_CR107","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1210\/jc.2016-1874","volume":"101","author":"J Vouillarmet","year":"2016","unstructured":"Vouillarmet, J. et al. Aldosterone-producing adenoma with a somatic KCNJ5 mutation revealing APC-dependent familial adenomatous polyposis. J. Clin. Endocrinol. Metab. 101, 3874\u20133878 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR108","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/jc.2005-0681","volume":"90","author":"M Stowasser","year":"2005","unstructured":"Stowasser, M. et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J. Clin. Endocrinol. Metab. 90, 5070\u20135076 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR109","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/en.2013-1944","volume":"155","author":"P Tauber","year":"2014","unstructured":"Tauber, P. et al. Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas. Endocrinology 155, 1353\u20131362 (2014).","journal-title":"Endocrinology"},{"key":"382_CR110","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","volume":"127","author":"UI Scholl","year":"2017","unstructured":"Scholl, U. I. et al. Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma. J. Clin. Invest. 127, 2739\u20132750 (2017).","journal-title":"J. Clin. Invest."},{"key":"382_CR111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/HYPERTENSIONAHA.115.06186","volume":"67","author":"TA Williams","year":"2016","unstructured":"Williams, T. A. et al. Genotype-specific steroid profiles associated with aldosterone-producing adenomas. Hypertension 67, 139\u2013145 (2016).","journal-title":"Hypertension"},{"key":"382_CR112","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/EJE-13-0551","volume":"169","author":"A Osswald","year":"2013","unstructured":"Osswald, A. et al. Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. Eur. J. Endocrinol. 169, 657\u2013663 (2013).","journal-title":"Eur. J. Endocrinol."},{"key":"382_CR113","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1210\/jc.2015-3284","volume":"101","author":"T Kitamoto","year":"2016","unstructured":"Kitamoto, T. et al. Clinical and steroidogenic characteristics of aldosterone-producing adenomas with ATPase or CACNA1D gene mutations. J. Clin. Endocrinol. Metab. 101, 494\u2013503 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/JME-15-0324","volume":"57","author":"NG Hattangady","year":"2016","unstructured":"Hattangady, N. G. et al. Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production. J. Mol. Endocrinol. 57, 1\u201311 (2016).","journal-title":"J. Mol. Endocrinol."},{"key":"382_CR115","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/HYPERTENSIONAHA.118.12064","volume":"73","author":"Y Tezuka","year":"2019","unstructured":"Tezuka, Y. et al. 18-Oxocortisol synthesis in aldosterone-producing adrenocortical adenoma and significance of KCNJ5 mutation status. Hypertension 73, 1283\u20131290 (2019).","journal-title":"Hypertension"},{"key":"382_CR116","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130356","volume":"4","author":"M Murakami","year":"2019","unstructured":"Murakami, M. et al. In situ metabolomics of aldosterone-producing adenomas. JCI Insight 4, e130356 (2019).","journal-title":"JCI Insight"},{"key":"382_CR117","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/08037051.2018.1436961","volume":"27","author":"G Maiolino","year":"2018","unstructured":"Maiolino, G. et al. Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism. Blood Press. 27, 200\u2013205 (2018).","journal-title":"Blood Press."},{"key":"382_CR118","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena, C. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 168, 80\u201385 (2008).","journal-title":"Arch. Intern. Med."},{"key":"382_CR119","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke, M. et al. Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension 60, 618\u2013624 (2012).","journal-title":"Hypertension"},{"key":"382_CR120","volume":"6","author":"VC Wu","year":"2016","unstructured":"Wu, V. C. et al. Long term outcome of aldosteronism after target treatments. Sci. Rep. 6, 32103 (2016).","journal-title":"Sci. Rep."},{"key":"382_CR121","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2009-1763","volume":"95","author":"N Sukor","year":"2010","unstructured":"Sukor, N., Kogovsek, C., Gordon, R. D., Robson, D. & Stowasser, M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 95, 1360\u20131364 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR122","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0031-1299681","volume":"44","author":"O Steichen","year":"2012","unstructured":"Steichen, O., Zinzindohoue, F., Plouin, P. F. & Amar, L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm. Metab. Res. 44, 221\u2013227 (2012).","journal-title":"Horm. Metab. Res."},{"key":"382_CR123","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"Rossi, G. P. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 62, 62\u201369 (2013).","journal-title":"Hypertension"},{"key":"382_CR124","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"Williams, T. A. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 5, 689\u2013699 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"382_CR125","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.surg.2019.08.017","volume":"167","author":"YH Chang","year":"2020","unstructured":"Chang, Y. H. et al. Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism. Surgery 167, 367\u2013377 (2020).","journal-title":"Surgery"},{"key":"382_CR126","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","volume":"71","author":"GP Rossi","year":"2018","unstructured":"Rossi, G. P. et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 71, 585\u2013591 (2018).","journal-title":"Hypertension"},{"key":"382_CR127","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2011.12.003","volume":"221","author":"YH Lin","year":"2012","unstructured":"Lin, Y. H. et al. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclerosis 221, 154\u2013159 (2012).","journal-title":"Atherosclerosis"},{"key":"382_CR128","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/HJH.0b013e3283550f93","volume":"30","author":"YH Lin","year":"2012","unstructured":"Lin, Y. H. et al. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J. Hypertens. 30, 1606\u20131613 (2012).","journal-title":"J. Hypertens."},{"key":"382_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.10.002","author":"H Komada","year":"2020","unstructured":"Komada, H. et al. Insulin secretion and sensitivity before and after surgical treatment for aldosterone-producing adenoma. Diabetes Metab. 46, 236\u2013242 (2020).","journal-title":"Diabetes Metab"},{"key":"382_CR130","doi-asserted-by":"crossref","first-page":"E878","DOI":"10.1210\/jc.2010-2723","volume":"96","author":"N Sonino","year":"2011","unstructured":"Sonino, N. et al. Psychological assessment of primary aldosteronism: a controlled study. J. Clin. Endocrinol. Metab. 96, E878\u2013E883 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/15622975.2012.665480","volume":"15","author":"K Apostolopoulou","year":"2014","unstructured":"Apostolopoulou, K. et al. Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross-sectional study. World J. Biol. Psychiatry 15, 26\u201335 (2014).","journal-title":"World J. Biol. Psychiatry"},{"key":"382_CR132","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2017-01442","volume":"103","author":"M Velema","year":"2018","unstructured":"Velema, M. et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J. Clin. Endocrinol. Metab. 103, 16\u201324 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR133","doi-asserted-by":"crossref","DOI":"10.1186\/s12893-018-0432-1","volume":"18","author":"M Citton","year":"2019","unstructured":"Citton, M., Viel, G., Torresan, F., Rossi, G. P. & Iacobone, M. Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism. BMC Surg. 18, 105 (2019).","journal-title":"BMC Surg."},{"key":"382_CR134","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/iju.14016","volume":"26","author":"S Ishidoya","year":"2019","unstructured":"Ishidoya, S. et al. Changes in quality of life after laparoscopic adrenalectomy for patients with primary aldosteronism: prospective 2-year longitudinal cohort study in a Japanese tertiary center. Int. J. Urol. 26, 752\u2013753 (2019).","journal-title":"Int. J. Urol."},{"key":"382_CR135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/EC-19-0026","volume":"8","author":"MS Velema","year":"2019","unstructured":"Velema, M. S. et al. A disease-specific quality of life questionnaire for primary aldosteronism. Endocr. Connect. 8, 389\u2013397 (2019).","journal-title":"Endocr. Connect."},{"key":"382_CR136","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1210\/js.2019-00295","volume":"3","author":"M Morisaki","year":"2019","unstructured":"Morisaki, M. et al. Predictors of clinical success after surgery for primary aldosteronism in the Japanese nationwide cohort. J. Endocr. Soc. 3, 2012\u20132022 (2019).","journal-title":"J. Endocr. Soc."},{"key":"382_CR137","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1210\/jc.2019-00531","volume":"104","author":"LAP Vilela","year":"2019","unstructured":"Vilela, L. A. P. et al. KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 104, 4695\u20134702 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR138","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"Parthasarathy, H. K. et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. 29, 980\u2013990 (2011).","journal-title":"J. Hypertens."},{"key":"382_CR139","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","volume":"9","author":"A Karagiannis","year":"2008","unstructured":"Karagiannis, A. et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert. Opin. Pharmacother. 9, 509\u2013515 (2008).","journal-title":"Expert. Opin. Pharmacother."},{"key":"382_CR140","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.jacc.2019.09.057","volume":"74","author":"GP Rossi","year":"2019","unstructured":"Rossi, G. P. Primary aldosteronism: JACC state-of-the-art review. J. Am. Coll. Cardiol. 74, 2799\u20132811 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"382_CR141","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre, X. et al. Efficacy and tolerance of spironolactone in essential hypertension. Am. J. Cardiol. 60, 820\u2013825 (1987).","journal-title":"Am. J. Cardiol."},{"key":"382_CR142","first-page":"650","volume":"240","author":"M de Gasparo","year":"1987","unstructured":"de Gasparo, M. et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650\u2013656 (1987).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"382_CR143","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","volume":"25","author":"ED Burgess","year":"2003","unstructured":"Burgess, E. D. et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin. Ther. 25, 2388\u20132404 (2003).","journal-title":"Clin. Ther."},{"key":"382_CR144","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40620-019-00600-7","volume":"33","author":"I Capelli","year":"2020","unstructured":"Capelli, I. et al. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J. Nephrol. 33, 37\u201348 (2020).","journal-title":"J. Nephrol."},{"key":"382_CR145","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero, P. et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 98, 4826\u20134833 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"382_CR146","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M. & Vaidya, A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 6, 51\u201359 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"382_CR147","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","volume":"3","author":"GL Hundemer","year":"2018","unstructured":"Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M. & Vaidya, A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 3, 768\u2013774 (2018).","journal-title":"JAMA Cardiol."},{"key":"382_CR148","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","volume":"72","author":"GL Hundemer","year":"2018","unstructured":"Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M. & Vaidya, A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72, 658\u2013666 (2018).","journal-title":"Hypertension"},{"key":"382_CR149","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","volume":"39","author":"A Vaidya","year":"2018","unstructured":"Vaidya, A., Mulatero, P., Baudrand, R. & Adler, G. K. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr. Rev. 39, 1057\u20131088 (2018).","journal-title":"Endocr. Rev."},{"key":"382_CR150","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/HYPERTENSIONAHA.117.10226","volume":"70","author":"B Caroccia","year":"2017","unstructured":"Caroccia, B. et al. Macrolides blunt aldosterone biosynthesis: a proof-of-concept study in KCNJ5 mutated adenoma cells ex vivo. Hypertension 70, 1238\u20131242 (2017).","journal-title":"Hypertension"},{"key":"382_CR151","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn, J. W. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 45, 3\u201317 (1955).","journal-title":"J. Lab. Clin. Med."},{"key":"382_CR152","first-page":"215","volume":"68","author":"JW Conn","year":"1955","unstructured":"Conn, J. W. & Louis, L. H. Primary aldosteronism: a new clinical entity. Trans. Assoc. Am. Physicians 68, 215\u2013231 (1955).","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"382_CR153","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1440-1681.1991.tb01446.x","volume":"18","author":"RD Gordon","year":"1991","unstructured":"Gordon, R. D. et al. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin. Exp. Pharmacol. Physiol. 18, 283\u2013286 (1991).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"382_CR154","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","volume":"93","author":"JW Funder","year":"2008","unstructured":"Funder, J. W. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266\u20133281 (2008).","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41574-020-0382-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41574-020-0382-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41574-020-0382-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T18:49:52Z","timestamp":1723315792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-020-0382-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":154,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1038\/s41574-020-0382-4","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"17 June 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}